CD154 is transiently expressed by activated T cells and interacts with CD40 on B cells, dendritic cells, macrophages, and monocytes. This costimulatory receptor-ligand couple seems decisive in Ag-driven immune responses but may be differentially involved in type 1 vs type 2 responses. We studied the importance of CD40-CD154 in both responses using the reporter Ag popliteal lymph node assay in which selectively acting drugs generate clearly polarized type 1 (streptozotocin) or type 2 (D-penicillamine, diphenylhydantoin) responses to a constant coinjected Ag in the same mouse strain. Treatment of mice with anti-CD154 reduced characteristic immunological parameters in type 2 responses (B and CD4+ T cell proliferation, IgG1 and IgE Abs, and IL-4 secretion) and only slightly affected the type 1 response (small decrease in IFN-γ production, influx of CD11c+ and F4/80+ cells, and prevention of architectural disruption of the lymph node, but no effect on IgG2a Ab and TNF-α secretion or B and CD4+ T cell proliferation). The findings indicate that the CD40-CD154 costimulatory interaction is a prerequisite in drug-induced type 2 responses and is only marginally involved in type 1 responses. The observed expression patterns of CD80 and CD86 on different APC (B cells in type 2 and dendritic cells in type 1) may be responsible for this discrepancy.
associated with human oral squamous cell carcinomas (OSCCs). Here, we show that restoration of DOC1 expression in OSCCs leads to a reversal of Epithelial-mesenchymal transition (EMT). Material and methods We examined DOC1 expression in normal and cancerous tongue tissue with immunohistochemistry. Besides, 4 different human OSCC cell lines were examined using immunofluorescence and immunoblotting. To study its role in these cells, we re-expressed DOC1 and utilised shRNA-mediated knockdowns (remodelers, EMT regulators). Subsequently we carried out proteomics, genomics, cell-based and biochemistry assays. Results and discussions The loss of DOC1 in oral cancer cells leads to a failure of NURD to bind and repress master transcriptional regulators of EMT. Re-expression of DOC1 in OSCC cells restores NURD recruitment to key target genes, a switch from open to closed chromatin, transcriptional repression, and reversal of EMT (MET). We speculate that, during the development of oral cancer, DOC1 is lost after the inactivation of p53 and INK4a. Our genome-wide binding site analysis showed that DOC1 is crucial for NURD recruitment to a subset of target loci; in particular, promoter regions harbouring CpG islands. DOC1-mediated NURD binding to the Twist1/2 and Zeb2 promoters leads to eviction of SWI/SNF involving nucleosome repositioning, epigenetic reprogramming, and shutdown of transcription. Binding of either SWI/SNF or NURD determines opposite epigenetic states, thereby committing OSCC cells to either EMT or MET. Conclusion Re-expression of DOC1 in OSCC cells restores the switch from open-to closed chromatin and reversal of EMT. We suggest that subunit-dependent gene selection is a major cause of the association between the loss of specific remodeler subunits and particular types of cancer. Our results emphasise that gene control involves a dynamic equilibrium between opposing chromatin modulating enzymes rather than a static chromatin state. Disturbances in this balance can initiate a cascade of chromatin reprogramming events that drives oncogenesis.
Methods: For in vitro cytotoxicity assays, MORAb-109 was evaluated in 5-day assays using various tumor cell lines. Tumor-cell line-derived and patient-derived in vivo tumor effiicacy studies were performed in immunocomprimized mice, Treatment was done via i.v. injection when tumors reached w 150-200 mm 3 . PK assays were performed in tumor-bearing mice, with detection of ADC by ligand-binding assay. Stability assays were performed in both plasma and serum from various species using a DAR-sensitive biolayer inferometry binding assay.Results: In vitro, MORAb-109 demonstrated selective cytotoxicity on a number of mesothelin-expressing tumor cell lines compared with non-expressing lines, with an improved specificity ratio compared with a competitor ADC. MORAb-109 exhibited dose-dependent anti-tumor activity in vivo, with regression observed in multiple tumor cell line and patient-derived xenograft models, including models with heterogeneous mesothelin expression. The ADC demonstrated good stability in matrix from multiple species in vitro, with limited (< 20%) payload release after 10-day incubation.Conclusions: Based on these findings, MORAb-109 is being considered for further development as a targeted therapy for mesothelin-expressing tumors.Legal entity responsible for the study: Eisai Inc.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.